10x Genomics Inc’s filing revealed that its Chief Executive Officer Saxonov Serge unloaded Company’s shares for reported $0.21 million on Mar 04 ’24. In the deal valued at $44.00 per share,4,660 shares were sold. As a result of this transaction, Saxonov Serge now holds 842,900 shares worth roughly $31.5 million.
Then, Saxonov Serge sold 2,821 shares, generating $130,737 in total proceeds. Upon selling the shares at $46.34, the Chief Executive Officer now owns 847,560 shares.
Before that, Hindson Benjamin J. sold 2,613 shares. 10x Genomics Inc shares valued at $121,098 were divested by the insider at a price of $46.34 per share. As a result of the transaction, Hindson Benjamin J. now holds 283,059 shares, worth roughly $10.58 million.
Guggenheim initiated its 10x Genomics Inc [TXG] rating to a Buy in a research note published on December 14, 2023; the price target was $60. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. BofA Securities also remained covering TXG and has increased its forecast on December 12, 2023 with a “Neutral” recommendation from previously “an Underperform” rating.
Price Performance Review of TXG
On Tuesday, 10x Genomics Inc [NASDAQ:TXG] saw its stock jump 2.38% to $37.37. Over the last five days, the stock has gained 3.49%. 10x Genomics Inc shares have fallen nearly -33.22% since the year began. Nevertheless, the stocks have fallen -28.22% over the past one year. While a 52-week high of $63.57 was reached on 01/02/24, a 52-week low of $33.79 was recorded on 04/05/24. SMA at 50 days reached $41.93, while 200 days put it at $46.44. A total of 0.73 million shares were traded, compared to the trading of 1.19 million shares in the previous session.
Levels Of Support And Resistance For TXG Stock
The 24-hour chart illustrates a support level at 36.80, which if violated will result in even more drops to 36.23. On the upside, there is a resistance level at 37.84. A further resistance level may holdings at 38.30. The Relative Strength Index (RSI) on the 14-day chart is 43.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.02, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 48.01%. Stochastics %K at 35.49% indicates the stock is a holding.
How much short interest is there in 10x Genomics Inc?
A steep rise in short interest was recorded in 10x Genomics Inc stocks on Mar 15, 2024, growing by 2.16 million shares to a total of 8.58 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 6.42 million shares. There was a rise of 25.17%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 10.23% of the overall stock float, the days-to-cover ratio (short ratio) rose to 6.1.
The most recent change occurred on May 10, 2023 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $65 price target.
